Jagdeep Nanchahal

Professor Jagdeep Nanchahal is a surgeon scientist whose research emphasizes the understanding of molecular mechanisms of common disease and translation of the findings to clinical trials. The current research interest of Nanchahal focuses on promoting tissue regeneration by targeting endogenous stem cells and reducing fibrosis. His group managed to characterize a novel mechanism for promoting repair and regeneration multiple using endogenous stem cells as the target. In 2013, Nanchahal’s group identified TNF (Tumor Necrosis Factor) as a druggable target for treating Dupuytrn’s disease, and they are leading a phase 2b clinical trial of the anti-TNF treatment.

Lab Information

University of Oxford

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Stem Cells 0 TNF 0 Tissue Regeneration 0 Dupuytren’s Disease 0 Molecular Biology 0 Hand Surgery 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (0)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Layton TB, Williams L, McCann F, et al. Author Correction: Cellular census of human fibrosis defines functionally distinct stromal cell types and states. Nat Commun. 2020;11(1):3275. Published 2020 Jun 24. doi:10.1038/s41467-020-17073-z

  2. Berner JE, Will P, Geoghegan L, Troisi L, Nanchahal J, Jain A. Safety and effectiveness of early compression of free flaps following lower limb reconstruction: A systematic review [published online ahead of print, 2020 Jun 9]. J Plast Reconstr Aesthet Surg. 2020;S1748-6815(20)30195-9. doi:10.1016/j.bjps.2020.05.011

  3. Layton TB, Williams L, McCann F, et al. Cellular census of human fibrosis defines functionally distinct stromal cell types and states [published correction appears in Nat Commun. 2020 Jun 24;11(1):3275]. Nat Commun. 2020;11(1):2768. Published 2020 Jun 2. doi:10.1038/s41467-020-16264-y

  4. Izadi D, Layton TB, Williams L, et al. Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis. Sci Adv. 2019;5(12):eaay0370. Published 2019 Dec 4. doi:10.1126/sciadv.aay0370

  5. Layton T, Nanchahal J. Recent advances in the understanding of Dupuytren's disease. F1000Res. 2019;8:F1000 Faculty Rev-231. Published 2019 Feb 28. doi:10.12688/f1000research.17779.1

  6. Nanchahal J, Ball C, Davidson D, et al. Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. EBioMedicine. 2018;33:282-288. doi:10.1016/j.ebiom.2018.06.022

  7. Verjee LS, Verhoekx JS, Chan JK, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A. 2013;110(10):E928-E937. doi:10.1073/pnas.1301100110


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists


This guy has no follower now.

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud